Patients who receive lenvatinib plus pembrolizumab for advanced renal cell carcinoma report similar or better health-related quality of life than those who receive sunitinib, show data from the phase 3 CLEAR trial.

Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.

The decision follows on from the placebo-controlled S-TRAC trial that showed a significant improvement in disease-free survival with sunitinib, at a median of 6.8 years versus 5.6 years for the placebo arm.

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.

Adjuvant treatment with sunitinib or sorafenib does not prolong disease-free survival or overall survival in clear cell renal cell carcinoma patients classed as high risk, shows a post hoc analysis of the placebo-controlled ASSURE trial.

Combination therapy with pembrolizumab plus axitinib results in similar health-related quality of life outcomes to that with sunitinib monotherapy for untreated advanced renal cell carcinoma, KEYNOTE-426 study data show.

The latest findings from the CheckMate 9ER trial show that the combination of nivolumab plus cabozantinib continues to offer superior survival to that of sunitinib for patients with treatment-naïve advanced renal cell carcinoma after a median follow-up of 32.9 months.

The most common multikinase inhibitor in the cohort was regorafenib, used in four patients, with cabozantinib, lenvatinib, sorafenib, and sunitinib used in one patient each.

There was no such relationship between troponin T levels and MACE risk in the sunitinib arm, and “[o]ccurrence of MACE did not correlate with baseline levels of other cardiac biomarkers in either arm,” say Rini and colleagues.

Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs.

People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.

And a similar pattern was observed for the 720 participants of the JAVELIN Renal 101 trial that compared avelumab plus axitinib with sunitinib.

This decision follows the positive results of the phase 3 CLEAR trial , which showed a significant progression-free and overall survival benefit with use of lenvatinib plus pembrolizumab relative to sunitinib.

Janet Brown, from the University of Sheffield in the UK, explained that STAR is a phase 2/3 trial in which patients with newly diagnosed metastatic (RCC) from 60 centers across the UK were randomly assigned to receive a conventional continuation strategy (CCS; n=461) or a drug-free interval strategy (DFIS; n=458) for treatment with sunitinib or pazopanib.

The objective response rate was also significantly higher with the combination than sunitinib.